TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.118nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.137nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.144nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.270nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.308nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.376nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.403nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.408nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.455nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.508nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.514nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.533nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.580nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.621nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.714nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.803nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.847nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.899nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1.02nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1.11nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1.29nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2.95nMAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair